

CITATION REPORT

List of articles citing

Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial

DOI: 10.2164/jandrol.04126

Journal of Andrology, 2005, 26, 310-8.

Source: <https://exaly.com/paper-pdf/39420165/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
52	Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials. <i>BJU International</i> , 2005 , 96, 857-63	5.6	13
51	Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. <i>Journal of Sexual Medicine</i> , 2005 , 2, 685-98	1.1	22
50	[Efficacy and safety of two dosing regimens with Tadalafil in Spanish men with erectile dysfunction: results from the SURE study in 14 European countries]. <i>Actas Urológicas Españolas</i> , 2006 , 30, 791-800	0.7	1
49	Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. <i>Urology</i> , 2006 , 68, 845-51	1.6	18
48	Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. <i>Urology</i> , 2006 , 68, 689-96	1.6	27
47	. 2006 ,		21
46	Oral Pharmacotherapy of Erectile Dysfunction. 75-93		5
45	Current World Literature. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2006 , 13, 310-317		
44	The effect of tadalafil on psychosocial outcomes in Swedish men with erectile distress: a multicentre, non-randomised, open-label clinical study. <i>International Journal of Clinical Practice</i> , 2006 , 60, 1386-93	2.9	16
43	Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction. <i>British Journal of Pharmacology</i> , 2006 , 147 Suppl 2, S41-55	8.6	30
42	Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. <i>Journal of Sexual Medicine</i> , 2006 , 3, 650-661	1.1	45
41	Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>European Urology</i> , 2006 , 50, 351-9	10.2	139
40	Headache: one of the most common and troublesome adverse reactions to drugs. <i>Current Drug Safety</i> , 2006 , 1, 43-58	1.4	17
39	Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury. <i>Archives of Neurology</i> , 2007 , 64, 1584-92		50
38	Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. <i>International Journal of Impotence Research</i> , 2007 , 19, 95-103	2.3	93
37	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <i>International Journal of Impotence Research</i> , 2007 , 19, 281-95	2.3	33
36	An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. <i>European Urology</i> , 2008 , 53, 1058-65	10.2	45

35	Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States. <i>Journal of Sexual Medicine</i> , 2008 , 5, 716-25	1.1	19
34	Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study. <i>Journal of Sexual Medicine</i> , 2008 , 5, 1708-19	1.1	12
33	Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2008 , 5, 2160-9	1.1	61
32	Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. <i>Current Medical Research and Opinion</i> , 2008 , 24, 3383-92	2.5	35
31	Cutaneous microcirculatory function predicts the responsiveness to tadalafil in patients with erectile dysfunction and coronary artery disease. <i>International Journal of Impotence Research</i> , 2008 , 20, 150-6	2.3	5
30	Sildenafil citrate efficacy 8 h postdose in men with mild to moderate erectile dysfunction. <i>International Journal of Impotence Research</i> , 2008 , 20, 388-95	2.3	4
29	Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. <i>International Journal of Impotence Research</i> , 2008 , 20, 333-42	2.3	37
28	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , 2008 , 5, 355-365		2
27	[Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis)]. <i>Folia Pharmacologica Japonica</i> , 2008 , 131, 469-77	0	1
26	Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. <i>Journal of Sexual Medicine</i> , 2009 , 6, 2039-48	1.1	51
25	Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study. <i>Journal of Sexual Medicine</i> , 2009 , 6, 2836-50	1.1	5
24	The management of erectile dysfunction with placebo only: does it work?. <i>Journal of Sexual Medicine</i> , 2009 , 6, 3440-8	1.1	21
23	Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study. <i>European Urology</i> , 2009 , 56, 1067-73	10.2	15
22	Toward a new PDE5 -optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2009 , 63, 1214-30	2.9	17
21	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2010 , 7, 524-40	1.1	132
20	cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. <i>Pharmacological Reviews</i> , 2010 , 62, 525-63	22.5	677
19	Modified intention to treat reporting in randomised controlled trials: systematic review. <i>BMJ, The</i> , 2010 , 340, c2697	5.9	130
18	Men with mild erectile dysfunction benefit from sildenafil treatment. <i>Journal of Sexual Medicine</i> , 2010 , 7, 3725-35	1.1	15

17	Do men with mild erectile dysfunction have the same risk factors as the general erectile dysfunction clinical trial population?. <i>BJU International</i> , 2011 , 107, 956-60	5.6	21
16	Silencing MaxiK activity in corporal smooth muscle cells initiates compensatory mechanisms to maintain calcium homeostasis. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2191-204	1.1	7
15	Rapid analysis of tadalafil in human blood plasma and seminal plasma by liquid chromatography/tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 77, 149-57	3.5	16
14	Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 1592-602	1.1	26
13	Fixed drug eruption caused by tadalafil--case report. <i>Anais Brasileiros De Dermatologia</i> , 2013 , 88, 617-9	1.6	7
12	Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. <i>International Journal of Impotence Research</i> , 2014 , 26, 223-9	2.3	12
11	Safety and efficacy of 20 mg pentadafil in Egyptian male patients with erectile dysfunction. <i>Human Andrology</i> , 2014 , 4, 38-43	1	
10	Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDAT study. <i>International Journal of Clinical Practice</i> , 2014 , 68, 1087-99	2.9	15
9	Expectations do not Influence the Response to Phosphodiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction. <i>Pharmacy (Basel, Switzerland)</i> , 2015 , 3, 295-306	2	
8	Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. <i>Current Medical Research and Opinion</i> , 2015 , 31, 379-89	2.5	9
7	Management of erectile dysfunction. 2018 , 545-554		
6	Predictors of Erectile Function Normalization in Men With Erectile Dysfunction Treated With Placebo. <i>Journal of Sexual Medicine</i> , 2018 , 15, 866-872	1.1	7
5	A new original nutraceutical formulation ameliorates the effect of Tadalafil on clinical score and cGMP accumulation. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021 , 93, 221-226	1.6	6
4	An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy. <i>Asian Journal of Andrology</i> , 2015 , 17, 61-7	2.8	12
3	A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. <i>Asian Journal of Andrology</i> , 2017 , 19, 500-504	2.8	5
2	Management of Erectile Dysfunction. 134-145		
1	Tadalafil Improves Haemodynamics and Arterial Stiffness but Not FlowMediated Dilation in Grade 1 Obesity. A Single-dose, Placebo-controlled Clinical Trial. 2022 , 20,		0